Pharvaris
A clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients.
By targeting the bradykinin-B2-receptor with novel small molecules, Pharvaris is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases.
In December 2023, Pharvaris announced positive top-line data from the CHAPTER-1 Phase II clinical study meeting its primary endpoint, with deucrictibant.
Latest Pharvaris News & Features
7 December 2023
23 August 2022
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze